DOCSLIB.ORG

Pentose Phosphate Pathway Biochemistry, Metabolism and Inherited Defects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Pentose phosphate pathway biochemistry, metabolism and inherited defects Amsterdam 2008 Mirjam M.C. Wamelink The research described in this thesis was carried out at the Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam, The Netherlands. The publication of this thesis was financially supported by: Department of Clinical Chemistry, VU University Medical Center Amsterdam E.C. Noyons Stichting ter bevordering van de Klinische Chemie in Nederland J.E. Jurriaanse Stichting te Rotterdam Printed by: Printpartners Ipskamp BV, Enschede ISBN: 978-90-9023415-1 Cover: Representation of a pathway of sugar Copyright Mirjam Wamelink, Amsterdam, The Netherlands, 2008 2 VRIJE UNIVERSITEIT Pentose phosphate pathway biochemistry, metabolism and inherited defects ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. L.M. Bouter, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de faculteit der Geneeskunde op donderdag 11 december 2008 om 13.45 uur in de aula van de universiteit, De Boelelaan 1105 door Mirjam Maria Catharina Wamelink geboren te Alkmaar 3 promotor: prof.dr.ir. C.A.J.M. Jakobs copromotor: dr. E.A. Struijs 4 Abbreviations 6PGD 6-phosphogluconate dehydrogenase ADP adenosine diphosphate ATP adenosine triphosphate CSF cerebrospinal fluid DHAP dihydroxyacetone phosphate G6PD glucose-6-phosphate dehydrogenase GA glyceraldehyde GAPDH glyceraldehyde-3-phosphate dehydrogenase GSG oxidized glutathione GSSG reduced glutathione LC-MS/MS liquid chromatography-tandem mass spectrometry MRI magnetic resonance imaging MRS magnetic resonance spectroscopy NAD(H) nicotinamide adenine dinucleotide (reduced) NADP(H) nicotinamide adenine dinucleotide phosphate (reduced) P phosphate(s) PPP pentose phosphate pathway ROS reactive oxygen species RPI ribose-5-phosphate isomerase TALDO transaldolase TPI triosephosphate isomerase 5 Contents Chapter 1 Outline of the thesis 7 Chapter 2 Quantification of sugar phosphate intermediates of the 13 pentose phosphate pathway by LC-MS/MS: application to two new inherited defects of metabolism. J. Chromatogr. B, 823 (2005) 18–25. Chapter 3 Analysis of polyols in urine by liquid chromatography- 29 tandem mass spectrometry: a useful tool for recognition of inborn errors affecting polyol metabolism. J. Inherit. Metab. Dis. 28 (2005) 951–963. Chapter 4 Detection of Transaldolase Deficiency by Quantitation of 45 Novel Seven-Carbon Chain Carbohydrate Biomarkers in Urine. J. Inherit. Metab. Dis. 30 (2007) 735–742. Chapter 5 Retrospective detection of transaldolase deficiency in 59 amniotic fluid: Implications for prenatal diagnosis. Prenat. Diagn. 28 (2008) 460-462. Chapter 6 Transaldolase deficiency in a 2 year-old boy with 65 cirrhosis. Mol. Genet. Metab. 94 (2008) 255-258. Chapter 7 Sedoheptulokinase deficiency due to a 57-kb deletion in 73 cystinosis patients causes urinary accumulation of sedoheptulose: Elucidation of the CARKL gene. Hum. Mutat. 29 (2008) 532-536. Chapter 8 Dynamic rerouting of the carbohydrate flux is key to 85 counteracting oxidative stress. J. Biol. 6 (2007) 10 Chapter 9 Biochemistry, metabolism and inherited defects of the 117 pentose phosphate pathway: a review. J. Inherit. Metab. Dis. In press. Chapter 10 Summary and discussion 145 Nederlandse samenvatting 153 Dankwoord 160 Curriculum Vitae 162 Publications 163 6 Chapter 1 Chapter 1 OUTLINE OF THE THESIS 7 Chapter 1 Outline of the thesis The pentose phosphate pathway (PPP) consists of two parts, which fulfil two distinct roles: an oxidative, non-reversible limb which allows reduction of NADP+ to NADPH while converting glucose-6-phosphate to a pentose- phosphate and CO2, and a non-oxidative, reversible limb, which connects pentose-phosphates to glycolytic intermediates. In recent years, two defects in the PPP have been discovered [1-3]. The first defect is deficiency of ribose-5-phosphate isomerase (RPI, OMIM 608611) and has been diagnosed in one patient, who presented with a slowly progressive leukoencephalopathy. The other defect is deficiency of transaldolase (TALDO, OMIM 606003). This defect is associated with liver dysfunction, whereas other organs are affected in various degrees. These two defects are very rare and although the defected enzymes are present in the same metabolic pathway, the PPP, the clinical phenotypes of both diseases are completely different. The main research goals concerning this thesis were: To characterize the normal pattern of metabolites involved in the PPP (polyols, sugars and sugar-phosphates (sugar-P)) and to diagnose new patients with abnormal metabolite profiles with a defect in the PPP To elucidate further the clinical phenotype and pathology of patients with TALDO deficiency To investigate the function of the PPP and its interrelationship with connected pathways. This thesis is divided in three sections. The biochemical methods designed to study normal and abnormal metabolite patterns of intermediates in the PPP are described in chapters 2-4. The research performed to diagnose new TALDO deficient patients and further characterisation of the clinical phenotype is described in chapter 5 and 6. In the third section we studied the function and routing through the PPP (chapter 7 and 8). The PPP is an inter-conversion of sugar-P. In the oxidative part glucose-6- phosphate is converted to a pentose-phosphate which is converted in the non-oxidative part into other sugar-P. To investigate the intracellular concentrations of sugar-P in patients with a defect in the PPP a new method was developed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). With this method described in chapter 2, the accumulation of sedoheptulose-7P in blood spots, fibroblasts and lymphoblasts of TALDO deficient patients could be identified. Furthermore, the LC-MS/MS method can be used for determining enzyme activities of 8 Chapter 1 the PPP by measuring the sugar-P involved as was done for TALDO and RPI deficiency. Polyols, or polyhydric alcohols, can be formed by the reduction of sugars and are classified based on the numbers of carbon (C) -atoms: erythritol and threitol (C4-polyols, tetritols), ribitol, arabitol and xylitol (C5-polyols, pentitols), galactitol, sorbitol and mannitol (C6-polyols, hexitols) and sedoheptitol and perseitol (C7-polyols, heptitols). Knowledge of the metabolism and function of most of the polyols is very limited. In TALDO deficiency elevated urinary concentrations of erythritol, arabitol and ribitol have been described [2]. In RPI deficiency arabitol and ribitol concentrations are highly elevated in urine, wheras xylitol is mildly elevated [1,3]. These two defects and other defects associated with the accumulation of polyols, like galactose-1-phosphate uridyltransferase deficiency, galactokinase deficiency, essential pentosuria and L- arabinosuria, can be diagnosed by the assessment of urinary concentrations of polyols. In chapter 3, two novel methods for the quantitative profiling of polyols in urine by LC-MS/MS are described. We started with the development of one method, which can be used as a quick screening method. The different polyol isomers elute as one peak and cannot be distinguished from each other. The second method uses the same sample preparation, however the use of another type of analytical liquid chromatography column makes separation of the different polyol isomers possible and thus enables the separate quantification of erythritol, threitol, ribitol, arabitol, xylitol, sorbitol, mannitol, galactitol, sedoheptitol and perseitol. In patients affected with TALDO deficiency, we previously also found increased amounts of a 7-carbon chain carbohydrate which we suspected of being sedoheptulose. In chapter 4 we describe the development of a LC-MS/MS method for identification and quantitation of the seven-carbon carbohydrates sedoheptulose and mannoheptulose in urine. Additionally, other seven-carbon chain carbohydrates were characterized in urine from controls and TALDO deficient patients, including sedoheptitol, perseitol and sedoheptulose-7P. The diagnosis of TALDO deficiency in a French family with four affected children born to the same consanguineous parents in 2006 expanded the number of TALDO deficient patients from two to six [4]. One of these patients presented in the antenatal period with hydrops fetalis with oligohydramnios. The pregnancy was medically terminated at 28 weeks gestation. In chapter 5 we retrospectively measured polyols, heptuloses and sedoheptulose-7P in the amniotic fluid sample of this fetus by LC- MS/MS. 9 Chapter 1 In chapter 6 we report the detailed clinical and biochemical presentation of a newly diagnosed patient with TALDO deficiency. As more patients are diagnosed, the clinical and biochemical phenotype of this disorder becomes more characterized and an overview is given in this chapter of all patients diagnosed together with the characteristics of the liver pathology. Little is known about the function of sedoheptulose and sedoheptulose-7P. Sedoheptulose-7P is one of the intermediates of the PPP and sedoheptulose and sedoheptulose-7P both accumulate in TALDO deficiency (chapter 2, 4-6). In chapter 7 we showed that patients with cystinosis caused by the common 57-kb deletion in the CTNS (cystinosin) gene excrete increased amounts of sedoheptulose in their urine. This 57-kb deletion also includes an adjacent gene CARKL. The CARKL gene encodes a protein that was predicted to function as a carbohydrate kinase.
Recommended publications
  • Oxidative Pentose Phosphate Pathway Enzyme 6-Phosphogluconate Dehydrogenase Plays a Key Role in Breast Cancer Metabolism

    Oxidative Pentose Phosphate Pathway Enzyme 6-Phosphogluconate Dehydrogenase Plays a Key Role in Breast Cancer Metabolism

    biology Article Oxidative Pentose Phosphate Pathway Enzyme 6-Phosphogluconate Dehydrogenase Plays a Key Role in Breast Cancer Metabolism Ibrahim H. Polat 1,2,3 ,Míriam Tarrado-Castellarnau 1,4 , Rohit Bharat 1, Jordi Perarnau 1 , Adrian Benito 1,5 , Roldán Cortés 1, Philippe Sabatier 2 and Marta Cascante 1,4,* 1 Department of Biochemistry and Molecular Biomedicine and Institute of Biomedicine (IBUB), Faculty of Biology, Universitat de Barcelona, Av Diagonal 643, 08028 Barcelona, Spain; [email protected] (I.H.P.); [email protected] (M.T.-C.); [email protected] (R.B.); [email protected] (J.P.); [email protected] (A.B.); [email protected] (R.C.) 2 Equipe Environnement et Prédiction de la Santé des Populations, Laboratoire TIMC (UMR 5525), CHU de Grenoble, Université Grenoble Alpes, 38700 CEDEX La Tronche, France; [email protected] 3 Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, 60590 Frankfurt, Germany 4 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28001 Madrid, Spain 5 Division of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 0NN, UK * Correspondence: [email protected] Simple Summary: Cancer cells alter their metabolism to maintain their high need for energy, produce Citation: Polat, I.H.; enough macromolecules for biosynthesis, and preserve their redox status. The investigation of Tarrado-Castellarnau, M.; Bharat, R.; cancer cell-specific metabolic alterations has vital importance to identify targets to be exploited for Perarnau, J.; Benito, A.; Cortés, R.; therapeutic development. The pentose phosphate pathway (PPP) is often highly activated in tumor Sabatier, P.; Cascante, M.
  • Hereditary Galactokinase Deficiency J

    Hereditary Galactokinase Deficiency J

    Arch Dis Child: first published as 10.1136/adc.46.248.465 on 1 August 1971. Downloaded from Alrchives of Disease in Childhood, 1971, 46, 465. Hereditary Galactokinase Deficiency J. G. H. COOK, N. A. DON, and TREVOR P. MANN From the Royal Alexandra Hospital for Sick Children, Brighton, Sussex Cook, J. G. H., Don, N. A., and Mann, T. P. (1971). Archives of Disease in Childhood, 46, 465. Hereditary galactokinase deficiency. A baby with galactokinase deficiency, a recessive inborn error of galactose metabolism, is des- cribed. The case is exceptional in that there was no evidence of gypsy blood in the family concerned. The investigation of neonatal hyperbilirubinaemia led to the discovery of galactosuria. As noted by others, the paucity of presenting features makes early diagnosis difficult, and detection by biochemical screening seems desirable. Cataract formation, of early onset, appears to be the only severe persisting complication and may be due to the biosynthesis and accumulation of galactitol in the lens. Ophthalmic surgeons need to be aware of this enzyme defect, because with early diagnosis and dietary treatment these lens changes should be reversible. Galactokinase catalyses the conversion of galac- and galactose diabetes had been made in this tose to galactose-l-phosphate, the first of three patient (Fanconi, 1933). In adulthood he was steps in the pathway by which galactose is converted found to have glycosuria as well as galactosuria, and copyright. to glucose (Fig.). an unexpectedly high level of urinary galactitol was detected. He was of average intelligence, and his handicaps, apart from poor vision, appeared to be (1) Galactose Gackinase Galactose-I-phosphate due to neurofibromatosis.
  • Lecture 7 - the Calvin Cycle and the Pentose Phosphate Pathway

    Lecture 7 - the Calvin Cycle and the Pentose Phosphate Pathway

    Lecture 7 - The Calvin Cycle and the Pentose Phosphate Pathway Chem 454: Regulatory Mechanisms in Biochemistry University of Wisconsin-Eau Claire 1 Introduction The Calvin cycle Text The dark reactions of photosynthesis in green plants Reduces carbon from CO2 to hexose (C6H12O6) Requires ATP for free energy and NADPH as a reducing agent. 2 2 Introduction NADH versus Text NADPH 3 3 Introduction The Pentose Phosphate Pathway Used in all organisms Glucose is oxidized and decarboxylated to produce reduced NADPH Used for the synthesis and degradation of pentoses Shares reactions with the Calvin cycle 4 4 1. The Calvin Cycle Source of carbon is CO2 Text Takes place in the stroma of the chloroplasts Comprises three stages Fixation of CO2 by ribulose 1,5-bisphosphate to form two 3-phosphoglycerate molecules Reduction of 3-phosphoglycerate to produce hexose sugars Regeneration of ribulose 1,5-bisphosphate 5 5 1. Calvin Cycle Three stages 6 6 1.1 Stage I: Fixation Incorporation of CO2 into 3-phosphoglycerate 7 7 1.1 Stage I: Fixation Rubisco: Ribulose 1,5- bisphosphate carboxylase/ oxygenase 8 8 1.1 Stage I: Fixation Active site contains a divalent metal ion 9 9 1.2 Rubisco Oxygenase Activity Rubisco also catalyzes a wasteful oxygenase reaction: 10 10 1.3 State II: Formation of Hexoses Reactions similar to those of gluconeogenesis But they take place in the chloroplasts And use NADPH instead of NADH 11 11 1.3 State III: Regeneration of Ribulose 1,5-Bisphosphosphate Involves a sequence of transketolase and aldolase reactions. 12 12 1.3 State III:
  • Biochemistry Entry of Fructose and Galactose

    Biochemistry Entry of Fructose and Galactose

    Paper : 04 Metabolism of carbohydrates Module : 06 Entry of Fructose and Galactose Dr. Vijaya Khader Dr. MC Varadaraj Principal Investigator Dr.S.K.Khare,Professor IIT Delhi. Paper Coordinator Dr. Ramesh Kothari,Professor UGC-CAS Department of Biosciences Saurashtra University, Rajkot-5, Gujarat-INDIA Dr. S. P. Singh, Professor Content Reviewer UGC-CAS Department of Biosciences Saurashtra University, Rajkot-5, Gujarat-INDIA Dr. Charmy Kothari, Assistant Professor Content Writer Department of Biotechnology Christ College, Affiliated to Saurashtra University, Rajkot-5, Gujarat-INDIA 1 Metabolism of Carbohydrates Biochemistry Entry of Fructose and Galactose Description of Module Subject Name Biochemistry Paper Name 04 Metabolism of Carbohydrates Module Name/Title 06 Entry of Fructose and Galactose 2 Metabolism of Carbohydrates Biochemistry Entry of Fructose and Galactose METABOLISM OF FRUCTOSE Objectives 1. To study the major pathway of fructose metabolism 2. To study specialized pathways of fructose metabolism 3. To study metabolism of galactose 4. To study disorders of galactose metabolism 3 Metabolism of Carbohydrates Biochemistry Entry of Fructose and Galactose Introduction Sucrose disaccharide contains glucose and fructose as monomers. Sucrose can be utilized as a major source of energy. Sucrose includes sugar beets, sugar cane, sorghum, maple sugar pineapple, ripe fruits and honey Corn syrup is recognized as high fructose corn syrup which gives the impression that it is very rich in fructose content but the difference between the fructose content in sucrose and high fructose corn syrup is only 5-10%. HFCS is rich in fructose because the sucrose extracted from the corn syrup is treated with the enzyme that converts some glucose in fructose which makes it more sweet.
  • RESPIRATION Pentose Phosphate Pathway Or Hexose Monophosphate Pathway

    RESPIRATION Pentose Phosphate Pathway Or Hexose Monophosphate Pathway

    RESPIRATION Pentose Phosphate Pathway or Hexose Monophosphate Pathway Pentose phosphate pathway or hexose monophosphate pathway (HMP pathway) is the other common pathway to break down glucose to pyruvate and operates in both aerobic and anaerobic conditions. This pathway produces NADPH, which carries chemical energy in the form of reducing power and is used almost universally as the reductant in anabolic (energy utilization) pathways (e.g., fatty acid biosynthesis, cholesterol biosynthesis, nucleotide biosynthesis) and detoxification pathways (e.g., reduction of oxidized glutathione, cytochrome P450 monooxygenases). Also, the pentose phosphate pathway generates pentose sugar ribose and its derivatives, which are necessary for the biosynthesis of nucleic acids (DNA and RNA) as well as ATP, NADH, FAD, and coenzyme A. In this way, though the pentose phosphate pathway may be a source of energy in many microorganisms, it is more often of greater importance in various biosynthetic pathways. Pentose phosphate pathway consists of two phases: the oxidative phase and the non-oxidative phase. Oxidative Phase: The oxidative phase of the pentose phosphate pathway initiates with the conversion of glucose 6- phosphate to 6-Phosphogluconate. NADP+ is the electron acceptor yielding NADPH during this reaction. 6-Phosphogluconate, a six-carbon sugar, is then oxidativelydecarboxylated to yield ribulose 5-phosphate, a five-carbon sugar. NADP+ is again the electron acceptor yielding NADPH. In the final step of oxidative phase, there is isomerisation of ribulose 5-phosphatc to ribose 5- phosphate by phosphopentose isomerase and the conversion of ribulose 5-phosphate into its epimerxylulose 5-phosphate by phosphopentose epimerase for the transketolase reaction in non- oxidative phase.
  • Carbohydrates: Structure and Function

    Carbohydrates: Structure and Function

    CARBOHYDRATES: STRUCTURE AND FUNCTION Color index: . Very important . Extra Information. “ STOP SAYING I WISH, START SAYING I WILL” 435 Biochemistry Team *هذا العمل ﻻ يغني عن المصدر المذاكرة الرئيسي • The structure of carbohydrates of physiological significance. • The main role of carbohydrates in providing and storing of energy. • The structure and function of glycosaminoglycans. OBJECTIVES: 435 Biochemistry Team extra information that might help you 1-synovial fluid: - It is a viscous, non-Newtonian fluid found in the cavities of synovial joints. - the principal role of synovial fluid is to reduce friction between the articular cartilage of synovial joints during movement O 2- aldehyde = terminal carbonyl group (RCHO) R H 3- ketone = carbonyl group within (inside) the compound (RCOR’) 435 Biochemistry Team the most abundant organic molecules in nature (CH2O)n Carbohydrates Formula *hydrate of carbon* Function 1-provides important part of energy Diseases caused by disorders of in diet . 2-Acts as the storage form of energy carbohydrate metabolism in the body 3-structural component of cell membrane. 1-Diabetesmellitus. 2-Galactosemia. 3-Glycogen storage disease. 4-Lactoseintolerance. 435 Biochemistry Team Classification of carbohydrates monosaccharides disaccharides oligosaccharides polysaccharides simple sugar Two monosaccharides 3-10 sugar units units more than 10 sugar units Joining of 2 monosaccharides No. of carbon atoms Type of carbonyl by O-glycosidic bond: they contain group they contain - Maltose (α-1, 4)= glucose + glucose -Sucrose (α-1,2)= glucose + fructose - Lactose (β-1,4)= glucose+ galactose Homopolysaccharides Heteropolysaccharides Ketone or aldehyde Homo= same type of sugars Hetero= different types Ketose aldose of sugars branched unBranched -Example: - Contains: - Contains: Examples: aldehyde group glycosaminoglycans ketone group.
  • Transaldolase B of Escherichia Coli K-12: Cloning of Its Gene, Talb, and Characterization of the Enzyme from Recombinant Strains

    Transaldolase B of Escherichia Coli K-12: Cloning of Its Gene, Talb, and Characterization of the Enzyme from Recombinant Strains

    JOURNAL OF BACTERIOLOGY, Oct. 1995, p. 5930–5936 Vol. 177, No. 20 0021-9193/95/$04.0010 Copyright q 1995, American Society for Microbiology Transaldolase B of Escherichia coli K-12: Cloning of Its Gene, talB, and Characterization of the Enzyme from Recombinant Strains GEORG A. SPRENGER,* ULRICH SCHO¨ RKEN, GERDA SPRENGER, AND HERMANN SAHM Institut fu¨r Biotechnologie 1, Forschungszentrum Ju¨lich GmbH, D-52425 Ju¨lich, Germany Received 7 June 1995/Accepted 7 August 1995 A previously recognized open reading frame (T. Yura, H. Mori, H. Nagai, T. Nagata, A. Ishihama, N. Fujita, K. Isono, K. Mizobuchi, and A. Nakata, Nucleic Acids Res. 20:3305–3308) from the 0.2-min region of the Escherichia coli K-12 chromosome is shown to encode a functional transaldolase activity. After cloning of the gene onto high-copy-number vectors, transaldolase B (D-sedoheptulose-7-phosphate:D-glyceraldehyde-3-phos- phate dihydroxyacetone transferase; EC 2.2.1.2) was overexpressed up to 12.7 U mg of protein21 compared with less than 0.1 U mg of protein21 in wild-type homogenates. The enzyme was purified from recombinant E. coli K-12 cells by successive ammonium sulfate precipitations (45 to 80% and subsequently 55 to 70%) and two anion-exchange chromatography steps (Q-Sepharose FF, Fractogel EMD-DEAE tentacle column; yield, 130 mg of protein from 12 g of cell wet weight) and afforded an apparently homogeneous protein band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with a subunit size of 35,000 6 1,000 Da. As the enzyme had a molecular mass of 70,000 Da by gel filtration, transaldolase B is likely to form a homodimer.
  • Dismetabolic Cataracts

    Dismetabolic Cataracts

    ndrom Sy es tic & e G n e e n G e f T o Journal of Genetic Syndromes Cavallini et al., J Genet Syndr Gene Ther 2013, 4:7 h l e a r n a r p u DOI: 10.4172/2157-7412.1000165 y o J & Gene Therapy ISSN: 2157-7412 Case Report Open Access Dismetabolic Cataracts: Clinicopathologic Overview and Surgical Management with B-MICS Technique Cavallini GM1, Forlini M1, Masini C1, Campi L1, Chiesi C1, Rejdak R2 and Forlini C3* 1Institute of Ophthalmology, University of Modena, Modena, Italy 2Department of Ophthalmology, Medical University of Lublin, Lublin, Poland 3Department of Ophthalmology, “Santa Maria Delle Croci” Hospital, Ravenna, Italy Abstract Background: Dismetabolic cataract is a loss of lens transparency due to an insult to the nuclear or lenticular fibers, caused by a metabolic disorder. The lens opacification may occur early or later in life, and may be isolated or associated to particular syndromes. We describe some of these metabolic conditions associated with cataract formation, and in particular we report our experience with a patient affected by lathosterolosis that presented bilateral cataracts. Methods: Our patient was a 7-years-old little girl diagnosed with lathosterolosis at age 2 years, through gas cromatography/mass spectrometry method for plasma sterol profile that revealed a peak corresponding to cholest- 7-en-3β-ol (lathosterol). Results: The lens samples obtained during surgical removal with B-MICS technique were sent to the Department of Pathology and routinely processed and stained with haematoxylin-eosin and PAS; then, they were examined under a light microscope. Histological examination revealed lens fragments with the presence of fibers disposed in a honeycomb way, samples characterized by the presence of homogeneous eosinophilic lens fibers, and other fragments characterized by bulgy elements referable to cortical fibers with degenerative characteristics.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Mitochondrial Involvement and Erythronic Acid As a Novel Biomarker in Transaldolase Deficiency Udo F.H

    Mitochondrial Involvement and Erythronic Acid As a Novel Biomarker in Transaldolase Deficiency Udo F.H

    Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopoulos, Daniel Rabier, Leo A.J. Kluijtmans, András Perl, Nanda M. Verhoeven-Duif, Pascale de Lonlay, Mirjam M.C. Wamelink, et al. To cite this version: Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopoulos, Daniel Rabier, et al.. Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2010, 1802 (11), pp.1028. 10.1016/j.bbadis.2010.06.007. hal-00623290 HAL Id: hal-00623290 https://hal.archives-ouvertes.fr/hal-00623290 Submitted on 14 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÔØ ÅÒÙ×Ö ÔØ Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopou- los, Daniel Rabier, Leo A.J. Kluijtmans, Andr´asPerl, Nanda M. Verhoeven- Duif, Pascale de Lonlay, Mirjam M.C. Wamelink, Cornelis Jakobs, Eva´ Morava, Ron A. Wevers PII: S0925-4439(10)00117-1 DOI: doi: 10.1016/j.bbadis.2010.06.007 Reference: BBADIS 63115 To appear in: BBA - Molecular Basis of Disease Received date: 23 April 2010 Revised date: 11 June 2010 Accepted date: 11 June 2010 Please cite this article as: Udo F.H.
  • Table S1. Disease Classification and Disease-Reaction Association

    Table S1. Disease Classification and Disease-Reaction Association

    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.
  • Galactosaemia in an Infant: Case Report F.V

    Galactosaemia in an Infant: Case Report F.V

    May 1999 EAST AFRICAN MEDICAL JOURNAL 28 1 East Atiican Medical Journal Vol. 76 No 5 May 1999 GALACTOSAEMIA IN AN INFANT: CASE REPORT F.V. Murila. MBChB. MMed, Lecturer, Department of Paediatrics and Child Health College of Health Sciences, University of Nairobi, P.O. Box 19676, Nairobi GALACTOSAEMIA IN AN INFANT: CASE REPORT F.V. MURILA SUMMARY Galactosaemia is a disorder of galactose metabolism in which raised levels of galactose and galactose-1-phosphate damage various organs. It is a very rare disease (incidence 1 in 60,000) and the diagnosis is often missed, leading to poor prognosis. A case of clinical galactosaemia that was diagnosed at the age of 11 months is reported. It is important to be aware of this condition as early treatment may prevent some of the complications. INTRODUCTION Assay of the respective enzyme in the red blood cell, white blood cell and fibroblasts shows a deficiency Galactosaemia is a very rare disorder of galactose of the enzyme(4). Red blood cells (RBC) lactose-l- metabolism whose mode of inheritance is autosomal phosphate levels are high(2). recessive(1). It is characterised by a deficiency of any Treatment consists of dietary restriction of lactose. of three enzymes. These are galactokinase, galactose- Inspite of strict lactose restriction, however, neurological I-phosphate uridyl transferase (GALT) and uridyl and gonadal damage are relentlessly progressive(2,5). diphosphogalactose-4-epimerase. A deficiency of galactokinase leads to an increase in serum galactose CASE REPORT - with subsequent galactosuria The excess galactose is converted to galactitol which leads to cataract formation. J.M.was well until the age of three months when he Intelligence is spared.